DELCATH SYSTEMS, INC. Logo

DELCATH SYSTEMS, INC.

Interventional oncology company treating liver cancers with targeted chemotherapy.

DCTH | US

Overview

Corporate Details

ISIN(s):
US24661P8077
LEI:
Country:
United States of America
Address:
566 QUEENSBURY AVENUE, 12804 QUEENSBURY

Description

Delcath Systems, Inc. is a commercial-stage interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes proprietary products for percutaneous hepatic perfusion (PHP), a minimally-invasive procedure designed to administer high-dose chemotherapy directly to the liver while controlling systemic exposure. Its flagship product in the United States is the HEPZATO KIT™ (melphalan/hepatic delivery system), an FDA-approved drug/device combination product for treating adult patients with metastatic uveal melanoma. In Europe, the company markets the CHEMOSAT® Hepatic Delivery System, a medical device for the same procedure.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-25 22:15 English 6.7 KB
2025-11-20 22:45
8-K
English 48.7 KB
2025-11-13 17:53 English 6.6 KB
2025-11-04 15:04
10-Q
English 1.3 MB
2025-11-04 14:02
8-K
English 93.6 KB
2025-10-20 12:01
8-K
English 146.5 KB
2025-10-18 00:05 English 12.4 KB
2025-08-15 22:46
S-8
English 64.8 KB
2025-08-15 22:15
8-K
English 132.4 KB
2025-08-06 15:14
10-Q
English 1.5 MB
2025-08-06 14:03
8-K
English 92.9 KB
2025-06-13 23:22 English 7.5 KB
2025-05-22 13:15
8-K
English 66.7 KB
2025-05-19 22:10 English 7.4 KB
2025-05-19 22:10 English 7.4 KB

Automate Your Workflow. Get a real-time feed of all DELCATH SYSTEMS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DELCATH SYSTEMS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DELCATH SYSTEMS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.